智通财经APP获悉，百奥赛图-B(02315)再涨超15%，年内累计涨幅已超150%。截至发稿，涨15.38%，报21.9港元，成交额1014.97万港元。
消息面上，6月5日，百奥赛图宣布旗下的全人抗体小鼠RenMab平台关键技术获得由日本专利局颁发的发明专利证书。目前RenMice已在美国等约8个国家获得专利授权，在15个国家和地区将近40项专利申请则处于审查阶段，未来有望陆续获得更多专利授权。据悉，百奥赛图已与德国默克、杨森/强生、百济神州等在内的约20家药企达成了RenMice平台授权合作。
此外，百奥赛图与南京正大天晴此前宣布，双方合作开发的NTB003（原代号BCG009）注射液已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，适应症为甲状腺眼病。据悉，NTB003注射液是百奥赛图与南京正大天晴合作开发的第二代全人抗IGF-1R抗体，由百奥赛图基于自主开发的全人抗体RenMab平台完成抗体发现和优化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.